New IV stopper aims to cut catheter complications in hospitals

NCT ID NCT07519304

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a needle-free connector with anti-reflux technology, a special stopper that prevents blood from flowing back into IV catheters. The goal is to see if it reduces complications like blockages, infections, and pain compared to standard connectors. The trial will involve 62 hospitalized adults who need a long peripheral catheter for at least a week.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Needle-free connector with anti-reflux technology (Clave™ Neutron™)

What this could lead to

If it works, this could reduce catheter-related complications such as blockages, infections, and pain, improving patient comfort and safety during hospital stays.

What could go wrong

This is a small early-stage trial with only 62 participants, so results may not apply to all patients. The device may not significantly reduce complications compared to standard connectors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RANDOMISED CONTROLLED TRIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bites and Stings thrombotic disease vascular occlusion disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••